BioVersys raised €23M in a Series C round in Jun 2022. The company is based in Basel, Switzerland. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
No investors disclosed for this round.
